No abstract

No abstract

A one-stage cross-longitudinal selective 1% study of the prevalence of clinical forms of anxiety and depression among AH patients; taking into account gender differences and the age of patients was conducted. As a comparison group, persons with no signs of AH were selected. The survey covered 10104 patients, including 3876 men and 6228 women. The dependence of the frequency and clinical form of anxiety and depression on the incidence of the AH population is proved, which determines the tactics and protocol for the treatment of patients with AH.

The aim of this study was evaluating the effect of the level attention and delayed reproduction on the quality of life in patients with cerebrovascular disease while taking various doses of cholecalciferol. 146 patients were examined, the average age of which was 59.8 ± 12.7 years. All patients were divided into three groups, depending on the dose of cholecalciferol administration. During the study, participants were assessed for the level of 25(OH) D, a neuropsychological examination and a study of the quality of life. Against the background of taking cholecalciferol at a dosage of 4000 IU per day, the level of 25(OH)D in blood serum signifcantly increased by 64.4 [12.5; 124.7] per cent (p < 0.001), and when taking 8000 IU per day – 131.8 [19.5; 298.4] per cent (p < 0.001) and its average value in the group reached an adequate level and amounted to 34.26 ± 11.22 ng/ml. In patients with cerebrovascular disease, the assessment of cognitive functions most often revealed violations in the assessment of delayed reproduction and attention. It was found that attention and delayed reproduction have a signifcantly signifcant relationship with most indicators in quality of life. Against the background of cholecalciferol therapy, a signifcantly signifcant improvement in attention and delayed reproduction was obtained when evaluated on neuropsychological scales, and there was also a signifcantly signifcant improvement in the quality of life when evaluated on the SF-36 questionnaire scale. Our study showed that the administration of cholecalciferol can improve the quality of life in patients with cerebrovascular disease.